About us

History

Forbion began in 2000 as ABN AMRO Capital Life Sciences, the venture arm of ABN AMRO Bank. In 2006, the team spun out to form the independent firm Forbion Capital Partners, backed by Coller Capital and ABN AMRO. In 2018, we streamlined our name to Forbion, reflecting our evolution into a leading European life sciences venture capital firm.

Closeup image of flower petal

Ripples in water

2024

4 exits over €1bn

Launch of Forbion BioEconomy Fund I

€2bn raised with €890 Forbion Ventures VII and €1.2bn Forbion Growth III

2022 – abstract genomic image

2022

Forbion raises €1.35b with €750m for Forbion Ventures VI and €600m for Forbion Growth Opportunities Fund II

€360m Growth Fund launched and closed

2021

Forbion Growth Opportunities Fund I launched and closed at €360m

2020 – €460m Venture Fund V closed

2020

Forbion Ventures Fund V €460m closed

2018 – €360m Venture Fund IV closed

2018

Forbion Ventures Fund IV €360m closed

2016 – €183m Venture Fund III closed

2016

Forbion Ventures Fund III €183m closed

€190m Venture Fund II closed

2010

Forbion Ventures Fund II €190m closed

German office opened in Munich

2006 – creation of Forbion Capital Partners

2006

The team spun out to form independent firm Forbion Capital Partners backed by Coller Capital and ABN AMRO

2000 – ABN Amro

2000

ABN AMRO Capital Life Sciences created from the venture arm of ABN AMRO Bank